AL3818: Clinical Trials

4 trials of AL3818, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 recruiting, 1 unknown. 4 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Completed 2, Recruiting 1, Unknown 1
Phase 22Completed 2

Follow AL3818: new trials by email Literature Review of AL3818 trials Research Report on AL3818

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
AL3818, Dacarbazine, AL3818 or placebo - Alveolar Soft Part Sarcoma, Leiomyosarcoma
Phase 3RecruitingAdvenchen Laboratories, LLC3252017-08-152026-02-25
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD) - Endometrial Carcinoma, Ovarian Carcinoma
Phase 3UnknownAdvenchen Laboratories, LLC2942015-12-012023-11-08
Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)
Anlotinib, Placebo - Non-small Cell Lung Cancer
Phase 2 / Phase 3CompletedChia Tai Tianqing Pharmaceutical Group Co., Ltd.4392015-02-262017-09-18
Study of Anlotinib in Patients With Metastatic Colorectal Cancer(mCRC)(ALTER0703)
Anlotinib, Placebo - Metastatic Colorectal Cancer
Phase 2 / Phase 3CompletedChia Tai Tianqing Pharmaceutical Group Co., Ltd.4192014-12-012019-05-21

Conditions studied

Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Fallopian Tube Neoplasms (1)  ·  Leiomyosarcoma (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Sarcoma (1)  ·  Sarcoma, Alveolar Soft Part (1)  ·  Sarcoma, Synovial (1)  ·  Uterine Cervical Neoplasms (1)

Sponsors

Advenchen Laboratories, LLC (2)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2)

Countries

China (4)  ·  Italy (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  United States (2)  ·  South Korea (1)

Top investigators

Baohui Han, professor (1)  ·  Jianqiang Cai, doctor (1)  ·  Jinwan Wang, doctor (1)  ·  Kai Lee, professor (1)  ·  Yihebali Chi, doctor (1)

Results publications

PMID 30032842, PMID 30098152, PMID 30392239, PMID 31689797, PMID 32077550, PMID 32944404, PMID 37185961